Belite Bio to present Phase 3 DRAGON topline results for tinlarebant in adolescent Stargardt disease at Euretina
Bitget2026/09/29 00:00- Belite Bio scheduled oral presentations at Euretina meetings in Vienna, including Phase 3 DRAGON topline results for tinlarebant in adolescent Stargardt disease.
- Results have not yet been presented; the Phase 3 readout is set for Oct. 4, 2026.
- The update is positioned as a pivotal trial outcome that could shape tinlarebant’s development path in inherited retinal disease.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Production Increase Falls Short, Layoffs First! Boeing (BA.US) Cuts 5% of Commercial Airplane Jobs, Delays 737 Monthly Production Target of 47 Aircraft to 2027
Stephanie Pope, head of Boeing's commercial airplanes division, informed employees in an internal memo on Monday that due to obstacles in increasing aircraft production, the division plans to cut 5% of its workforce.
After acquiring SpotHero, Uber (UBER.US) makes its debut in the parking sector with a parking space reservation feature, initially available in 15 U.S. cities
Uber has launched a brand new parking space reservation feature, which marks its first step in the parking sector following its acquisition of the parking app SpotHero earlier this year.
Arbitrum will welcome a new propAMM
Crypto prices
More
